Page 100 - 《中国药房》2024年8期

National Clinical Research Center of Kidney Diseases. Nephrol Renovasc Dis，2018，11：69-80.
Summary of China 2018 chronic kidney disease-mineral [13] ROZENTRYT P，NIEDZIELA J T，HUDZIK B，et al.
and bone disorder guideline[J]. Chin J Nephrol Dial Trans‐ Abnormal serum calcium levels are associated with clinical
plant，2019，28（1）：52-57. response to maximization of heart failure therapy[J]. Pol
[ 4 ] EVANS M，METHVEN S，GASPARINI A，et al. Cinacal‐ Arch Med Wewn，2015，125（1/2）：54-64.
cet use and the risk of cardiovascular events，fractures and [14] WARADY B A，NG E，BLOSS L，et al. Cinacalcet studies
mortality in chronic kidney disease patients with secon- in pediatric subjects with secondary hyperparathyroidism
dary hyperparathyroidism[J]. Sci Rep，2018，8（1）：2103. receiving dialysis[J]. Pediatr Nephrol，2020，35（9）：1679-
[ 5 ] MOROSETTI M，JANKOVIC L，ZAPPALÀ L，et al. 1697.
Long-term use of etelcalcetide for the treatment of secon- [15] KARABOYAS A，MUENZ D，HWANG Y，et al. Etelcal‐
dary hyperparathyroidism in patients undergoing hemo- cetide versus cinacalcet in hemodialysis patients in the
dialysis for end-stage renal failure：a real-life retrospective United States：a facility calcimimetic approach to assess
observational study[J]. Int Urol Nephrol，2023，55（7）： real-world effectiveness[J]. Kidney Med，2022，4（6）：
1865-1873. 100475.
[ 6 ] YOKOYAMA K，FUKAGAWA M，SHIGEMATSU T，et [16] WU W D，ZHOU H R，PESTKA J J. Potential roles for
al. Safety and efficacy of etelcalcetide，an intravenous cal‐ calcium-sensing receptor（CaSR）and transient receptor
cimimetic，for up to 52 weeks in hemodialysis patients potential ankyrin-1（TRPA1）in murine anorectic response
with secondary hyperparathyroidism：results of a post- to deoxynivalenol（vomitoxin）[J]. Arch Toxicol，2017，91
marketing surveillance in Japan[J]. Clin Exp Nephrol， （1）：495-507.
2021，25（1）：66-79. [17] DUFNER M M，KIRCHHOFF P，REMY C，et al. The
[ 7 ] PALMER S C，MAVRIDIS D，JOHNSON D W，et al. calcium-sensing receptor acts as a modulator of gastric
Comparative effectiveness of calcimimetic agents for secon- acid secretion in freshly isolated human gastric glands[J].
dary hyperparathyroidism in adults：a systematic review Am J Physiol Gastrointest Liver Physiol，2005，289（6）：
and network meta-analysis[J]. Am J Kidney Dis，2020，76 G1084-G1090.
（3）：321-330. [18] GOSWAMI S. Interplay of potassium channel，gastric
[ 8 ] NOGUCHI Y，NAGASAWA H，TACHI T，et al. Signal parietal cell and proton pump in gastrointestinal physiology，
detection of oral drug-induced dementia in chronic kidney pathology and pharmacology[J]. Minerva Gastroenterol，
disease patients using association rule mining and Bayesian 2022，68（3）：289-305.
confidence propagation neural network[J]. Pharmazie，2019， [19] YOUSAF F，CHARYTAN C. Review of cinacalcet hydro‐
74（9）：570-574. chloride in the management of secondary hyperparathy‐
[ 9 ] 张妮，王红力，钟贵遵，等 . 基于 BCPNN 法对培门冬酶 roidism[J]. Ren Fail，2014，36（1）：131-138.
和左旋门冬酰胺酶上市后安全警戒信号的挖掘与评价 [20] KOUBAR S H，QANNUS A A，MEDAWAR W，et al.
[J]. 中国药房，2021，32（16）：2012-2018. Hungry bone syndrome two weeks after starting cinacal‐
ZHANG N，WANG H L，ZHONG G Z，et al. Mining and cet：a call for caution[J]. CEN Case Rep，2018，7（1）：21-23.
evaluation of post-marketing safe alert signals of pegaspar‐ [21] KAMPSCHREUR L M，HOOGEVEEN E K，OP DEN
gase and L-asparaginase based on BCPNN method[J]. AKKER J W，et al. A haemodialysis patient with back
China Pharm，2021，32（16）：2012-2018. pain：brown tumour as a cause of spinal cord compression
[10] 陈文戈，李婵娟，江静，等 . 基于 BCPNN 法的药品不良 under cinacalcet therapy[J]. NDT Plus，2010，3（3）：
反应信号检测与自动预警技术研究[J]. 计算机应用研 291-295.
究，2009，26（4）：1394-1397. [22] EIDMAN K E，WETMORE J B. Treatment of secondary
CHEN W G，LI C J，JIANG J，et al. Research of signal hyperparathyroidism：how do cinacalcet and etelcalcetide
detection and automatic warning technology for adverse differ？[J]. Semin Dial，2018，31（5）：440-444.
drug reaction based on BCPNN method[J]. Appl Res Com‐ [23] DANESE M D，LUBECK D，BELOZEROFF V，et al.
put，2009，26（4）：1394-1397. Real world use and effects of calcimimetics in treating
[11] VAHE C，BENOMAR K，ESPIARD S，et al. Diseases mineral and bone disorder in hemodialysis patients[J]. Am
associated with calcium-sensing receptor[J]. Orphanet J J Nephrol，2020，51（10）：815-822.
Rare Dis，2017，12（1）：19. （收稿日期：2023-11-24 修回日期：2024-03-14）
[12] EIDMAN K E，WETMORE J B. Managing hyperparathy‐ （编辑：陈 宏）
roidism in hemodialysis：role of etelcalcetide[J]. Int J

· 990 · China Pharmacy 2024 Vol. 35 No. 8 中国药房 2024年第35卷第8期